A Single-centre, Open-label Study Testing the Safety and Performance of the Glyconics-SX System in Individuals With or Without Type 2 Diabetes
A Single-centre, Open-label Study Testing the Safety and Performance of the Glyconics-SX System in Individuals With or Without Type 2 Diabetes
The main clinical study objective is to retrieve initial high quality spectra measurements indicative of the accuracy of the Glyconics-SX System in distinguishing between individuals with or without T2DM based on known and/or assumed clinical status of the participants and as controlled by values of an internal biomarker indicative of glycaemia, HbA1c, as measured with validated, comparator device.
Inclusion Criteria:
Exclusion Criteria:
Individuals with any known medical conditions impacting either of the assessment methodology for glycaemia, such as
Any structural, deviating and visually detectable deviations in the appearance of the nails potentially impacting the spectra measurement, including
Any systemic or topical medication known to modify either the surface or structure of the nail or accuracy of HbA1c value.